Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA

Open source

DOI: 10.1038/s41591-024-03404-w
Published: 2024 Dec
Container: Nature medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03404-w,
  title = {Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.},
  author = {Horwitz SM and Nirmal AJ and Rahman J and Xu R and Drill E and Galasso N and Ganesan N and Davey T and Hancock H and Perez L and Maccaro C and Bahgat A and Marzouk E and Cathcart E and Moskowitz A and Noy A and Kumar A and Jacobsen E and Fisher DC and Mehta-Shah N and Kim YH and Khodadoust M and Kotlov N and Nikitina A and Kudryashova O and Zubareva V and Zornikova K and Shin N and Sorokina M and Degryse S and Postovalova E and Bagaev A and Hosszu K and McAvoy D and Boelens JJ and Wu W and Ciantra Z and Appelt JW and Trevisani C and Amaka S and Weinstock DM and Vardhana SA},
  year = {2024},
  journal = {Nature medicine},
  doi = {10.1038/s41591-024-03404-w},
  url = {https://doi.org/10.1038/s41591-024-03404-w}
}

RIS

TY  - JOUR
TI  - Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
AU  - Horwitz SM
AU  - Nirmal AJ
AU  - Rahman J
AU  - Xu R
AU  - Drill E
AU  - Galasso N
AU  - Ganesan N
AU  - Davey T
AU  - Hancock H
AU  - Perez L
AU  - Maccaro C
AU  - Bahgat A
AU  - Marzouk E
AU  - Cathcart E
AU  - Moskowitz A
AU  - Noy A
AU  - Kumar A
AU  - Jacobsen E
AU  - Fisher DC
AU  - Mehta-Shah N
AU  - Kim YH
AU  - Khodadoust M
AU  - Kotlov N
AU  - Nikitina A
AU  - Kudryashova O
AU  - Zubareva V
AU  - Zornikova K
AU  - Shin N
AU  - Sorokina M
AU  - Degryse S
AU  - Postovalova E
AU  - Bagaev A
AU  - Hosszu K
AU  - McAvoy D
AU  - Boelens JJ
AU  - Wu W
AU  - Ciantra Z
AU  - Appelt JW
AU  - Trevisani C
AU  - Amaka S
AU  - Weinstock DM
AU  - Vardhana SA
PY  - 2024
JO  - Nature medicine
DO  - 10.1038/s41591-024-03404-w
UR  - https://doi.org/10.1038/s41591-024-03404-w
ER  -

APA

SM, H., AJ, N., J, R., R, X., E, D., N, G., N, G., T, D., H, H., L, P., C, M., A, B., E, M., E, C., A, M., A, N., A, K., E, J., DC, F., N, M., YH, K., M, K., N, K., A, N., O, K., V, Z., K, Z., N, S., M, S., S, D., E, P., A, B., K, H., D, M., JJ, B., W, W., Z, C., JW, A., C, T., S, A., DM, W., & SA, V. (2024). Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.. Nature medicine. https://doi.org/10.1038/s41591-024-03404-w

Source records

pubmed · retrieved 2026-09-27T12:23:33.173Z